Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26379819
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Clinicopathological and prognostic significance of MUC4 expression in cancers:
evidence from meta-analysis
#MMPMID26379819
Huang X
; Wang X
; Lu SM
; Chen C
; Wang J
; Zheng YY
; Ren BH
; Xu L
Int J Clin Exp Med
2015[]; 8
(7
): 10274-83
PMID26379819
show ga
Mucin4 (MUC4) is a secreted glycoprotein. Numerous studies had indicated that
MUC4 was an attractive prognostic tumor biomarker. However, the results of
different studies have been inconsistent. So we conducted this meta-analysis to
explore the association between MUC4 expression and cancer prognosis. A
systematically comprehensive search was performed through PubMed, EMBASE and CNKI
(Chinese National Knowledge Infrastructure). Prognostic value of MUC4 expression
in malignancy patients was evaluated by pooled hazard ratios (HRs) and their 95%
confidence intervals (CIs). Meanwhile, pooled odds ratio (OR) with 95% CI was
appropriate for the association between MUC4 expression and clinicopathological
parameters. Eighteen studies including 1,933 patients were enrolled in this
meta-analysis. Significant association was found between elevated MUC4 expression
and poorer overall survival (OS) with pooled hazard ratio (HR) of 1.87 [95%
confidence interval (CI): 1.58-2.23, P<0.001]. Significant associations were also
detected in biliary tract carcinoma (HR: 2.41, 95% CI: 1.69-3.42, P<0.001),
pancreatic cancer (HR: 2.01, 95% CI: 1.42-2.86, P<0.001) and colorectal cancer
(HR: 1.73, 95% CI: 1.17-2.54, P=0.006). Moreover, combined odds ratio (OR) of
MUC4 indicated that MUC4 overexpression was associated with tumor stage, tumor
invasion and lymph node metastasis. Our results demonstrated that MUC4 may be
exploited as a novel prognostic biomarker for cancer patients.
free
free
free
